Citations

Clear

4 citation(s) found for "Goo, Young Ah".

Oncogenic deubiquitination controls tyrosine kinase signaling and therapy response in acute lymphoblastic leukemia
Jin, Qi , Gutierrez-Diaz, Blanca T. , Zhou, Yalu, Narang, Sonali , Fijalkwoski, Igor, Borin, Cristina , Laere, Jolien Van, Payton, Monique A. , Cho, Byoung-Kyu , Han, Cuijuan , Sun, Limin , Serafin, Valentina , Yacu, George, Veltri, Giulia , Dreveny, Ingrid , Goo, Young Ah , Safgren, Stephanie L. , Tsai, Yi-Chien , Bornhäuser, Beat , Suraneni, Praveen, Gaspar‐Maia, Alexandre , Kandela, Irawati , Crispino, John D. , Ntziachristos, Panagiotis , Gutierrez Diaz, Blanca , Pieters, Tim , Narang, Sonali , Fijalkwoski, Igor , Borin, Cristina , Payton, Monique , Cho, Byoung-Kyu , Han, Cuijuan , Sun, Limin , Serafin, Valentina , Von Loocke, Wouter , Veltri, Giulia , Dreveny, Ingrid , Ben-Sahra, Issam , Safgren, Stephanie L , Bornhauser, Beat , Gaspar-Maia, Alexandre , Van Vlierberghe, Pieter , Tsirigos, Aristotelis , Ntziachristos, Panagiotis , Crispino, John D , Jin, Qi , Basso, Giuseppe , Vlierberghe, Pieter Van , Tsirigos, Aristotelis

Mayo Clinic

Science Advances | December 9, 2022 | Volume: 8 | Issue: 49 | Pages: No page available

10.1126/sciadv.abq8437 | PMID 36490346 Get It

Dysregulation of kinase signaling pathways favors tumor cell survival and therapy resistance in cancer. Here, we reveal a posttranslational regulation of kinase signaling and nuclear receptor activity via deubiquitination in T cell acute lymphoblastic leukemia (T-ALL). We observed that the ubiquitin-specific protease 11 (USP11) is highly expressed and associates with poor prognosis in T-ALL. USP11 ablation inhibits leukemia progression in vivo, sparing normal hematopoiesis. USP11 forms a complex with USP7 to deubiquitinate the oncogenic lymphocyte cell–specific protein-tyrosine kinase (LCK) and enhance its activity. Impairment of LCK activity leads to increased glucocorticoid receptor (GR) expression and glucocorticoids sensitivity. Genetic knockout of USP7 improved the antileukemic efficacy of glucocorticoids in vivo. The transcriptional activation of GR target genes is orchestrated by the deubiquitinase activity and mediated via an increase in enhancer-promoter interaction intensity. Our data unveil how dysregulated deubiquitination controls leukemia survival and drug resistance, suggesting previously unidentified therapeutic combinations toward targeting leukemia.
Reinspection of a Clinical Proteomics Tumor Analysis Consortium (CPTAC) Dataset with Cloud Computing Reveals Abundant Post-Translational Modifications and Protein Sequence Variants
Prakash, Amol , Taylor, Lorne , Varkey, Manu, Hoxie, Nate , Mohammed, Yassene , Goo, Young Ah , Peterman, Scott, Yuan, Yuting , Glaros, Trevor , Steele, Joel R. , Faridi, Pouya , Parihari, Shashwati , Srivastava, Sanjeeva , Otto, Joseph J. , Semmes, O. John , Moran, Michael F. , Madugundu, Anil K. , Mun, Dong Gi, Pandey, Akhilesh , Mahoney, Keira E. , Shabanowitz, Jeffrey , Saxena, Satya, Steele, Joel R , Faridi, Pouya , Parihari, Shashwati , Srivastava, Sanjeeva , Semmes, O John , Moran, Michael F , Pandey, Akhilesh , Pandey, Akhilesh , Shabanowitz, Jeffrey , Moghekar, Abhay , Nyalwidhe, Julius O. , Orsburn, Benjamin C.

Mayo Clinic

Cancers | October 10, 2021 | Volume: 13 | Issue: 20 | Pages: 5034

10.3390/cancers13205034 | PMID 34680183 Get It

The Clinical Proteomic Tumor Analysis Consortium (CPTAC) has provided some of the most in-depth analyses of the phenotypes of human tumors ever constructed. Today, the majority of proteomic data analysis is still performed using software housed on desktop computers which limits the number of sequence variants and post-translational modifications that can be considered. The original CPTAC studies limited the search for PTMs to only samples that were chemically enriched for those modified peptides. Similarly, the only sequence variants considered were those with strong evidence at the exon or transcript level. In this multi-institutional collaborative reanalysis, we utilized unbiased protein databases containing millions of human sequence variants in conjunction with hundreds of common post-translational modifications. Using these tools, we identified tens of thousands of high-confidence PTMs and sequence variants. We identified 4132 phosphorylated peptides in nonenriched samples, 93% of which were confirmed in the samples which were chemically enriched for phosphopeptides. In addition, our results also cover 90% of the high-confidence variants reported by the original proteogenomics study, without the need for sample specific next-generation sequencing. Finally, we report fivefold more somatic and germline variants that have an independent evidence at the peptide level, including mutations in ERRB2 and BCAS1. In this reanalysis of CPTAC proteomic data with cloud computing, we present an openly available and searchable web resource of the highest-coverage proteomic profiling of human tumors described to date.
Posttranslational Regulation of the Exon Skipping Machinery Controls Aberrant Splicing in Leukemia
Zhou, Yalu, Han, Cuijuan , Wang, Eric , Lorch, Adam H., Serafin, Valentina , Cho, Byoung-Kyu , Gutierrez-Diaz, Blanca T. , Calvo, Julien , Fang, Celestia, Khodadadi‐Jamayran, Alireza , Tabaglio, Tommaso , Marier, Christian, Kuchmiy, Anna , Sun, Limin , Yacu, George, Filip, Szymon K. , Jin, Qi , Takahashi, Yoh-hei, Amici, David R. , Rendleman, Emily J. , Rawat, Radhika , Paganin, Maddalena , Kandela, Irawati , Politanska, Yuliya , Palhais, Bruno , Vlierberghe, Pieter Van , Taghon, Tom , Aifantis, Iannis , Goo, Young Ah , Guccione, Ernesto , Heguy, Adriana , Tsirigos, Aristotelis , Wee, Keng Boon , Mishra, Rama K. , Pflumio, Françoise , Accordi, Benedetta , Ntziachristos, Panagiotis , Jin, Qi , Taghon, Tom , Goo, Young Ah , Tsirigos, Aristotelis , Basso, Giuseppe , Khodadadi-Jamayran, Alireza , Van Vlierberghe, Pieter , Gutierrez Diaz, Blanca , Cho, Byoung-Kyu , Han, Cuijuan , Serafin, Valentina , Jin, Qi , Takahashi, Yoh-Hei, Bresolin, Silvia , Zhang, Cheng , Li, Hu , Abdala‐Valencia, Hiam , Mendillo, Marc L. , Zhu, Ping, Basso, Giuseppe , Jin, Qi

Mayo Clinic

Cancer Discovery | May 22, 2020 | Volume: 10 | Issue: 9 | Pages: 1388-1409

10.1158/2159-8290.cd-19-1436 | PMID 32444465 Get It

Abstract Splicing alterations are common in diseases such as cancer, where mutations in splicing factor genes are frequently responsible for aberrant splicing. Here we present an alternative mechanism for splicing regulation in T-cell acute lymphoblastic leukemia (T-ALL) that involves posttranslational stabilization of the splicing machinery via deubiquitination. We demonstrate there are extensive exon skipping changes in disease, affecting proteasomal subunits, cell-cycle regulators, and the RNA machinery. We present that the serine/arginine-rich splicing factors (SRSF), controlling exon skipping, are critical for leukemia cell survival. The ubiquitin-specific peptidase 7 (USP7) regulates SRSF6 protein levels via active deubiquitination, and USP7 inhibition alters the exon skipping pattern and blocks T-ALL growth. The splicing inhibitor H3B-8800 affects splicing of proteasomal transcripts and proteasome activity and acts synergistically with proteasome inhibitors in inhibiting T-ALL growth. Our study provides the proof-of-principle for regulation of splicing factors via deubiquitination and suggests new therapeutic modalities in T-ALL. Significance: Our study provides a new proof-of-principle for posttranslational regulation of splicing factors independently of mutations in aggressive T-cell leukemia. It further suggests a new drug combination of splicing and proteasomal inhibitors, a concept that might apply to other diseases with or without mutations affecting the splicing machinery. This article is highlighted in the In This Issue feature, p. 1241
Echocardiographic diagnosis of total or left congenital pericardial absence with positional change
Kim, Hyung‐Kwan , Jung, Ji-Hyun, Yoon, Yeonyee E. , Park, Jun-Bin, Lee, Seung‐Pyo , Kim, Yong‐Jin , Cho, Goo-Young, Oh, Jae K. , Park, Jun‐Bean , Kim, Min-Jeong , Yoon, Yeonyee Elizabeth , Kim, Hack‐Lyoung , Cho, Goo-Young, Sohn, Daewon , Kim, Hyung-Kwan

Mayo Clinic

Heart | March 9, 2017 | Volume: 103 | Issue: 15 | Pages: 1203-1209

10.1136/heartjnl-2016-310870 | PMID 28280147 Get It

Objectives Congenital absence of the pericardium (CAP) is often confused with other conditions presenting with right ventricular dilatation and usually warrants CT or cardiac MR (CMR) to confirm. It would be desirable to have more specific echocardiographic criteria to provide a conclusive diagnosis. Methods 11 patients who were diagnosed with CAP (four patients with total CAP) based on CT/CMR were consecutively enrolled. Thirteen patients with atrial septal defect (ASD) and 16 normal subjects served as controls. To investigate spatial changes of heart in the thoracic cavity in CAP, following echocardiographic measurements were made in the left and right decubitus positions: the angle between the ultrasound beam and the left ventricular posterior wall (Angle-PW) in end-diastole at the parasternal long axis, and the distance between the chest wall and the most distal part of the left ventricular posterior wall (Distance-PW) at the parasternal mid-ventricular short axis. Results Angle-PW in patients with CAP were significantly greater than in those with ASD (100.1±12.5° vs 74.5±8.6°, p<0.017) or in normal subjects (100.1±12.5° vs 69.9±7.6°, p<0.017) at the left decubitus, and the difference in Angle-PW according to posture (left vs right) was significantly greater in CAP compared with the other groups (CAP 20.7±12.7°, ASD 0.31±1.80°, normal 0.31±1.40°, all p<0.017). The differences in Distance-PW according to patient position (CAP 2.43±0.77°, ASD 0.42±0.45°, normal 0.26±0.55°) or cardiac cycle in each position (left: CAP 1.60±0.76°, ASD 0.41±0.27°, normal 0.17±0.12°; right: CAP 0.70±0.32°, ASD 0.22±0.19°, normal 0.22±0.13°) were significantly higher in the CAP group than in the other groups (all p<0.017). Conclusions Patients with CAP have dynamic alteration in cardiac position depending on posture, which is not observed in ASD or in normal controls. Hence, total or left-sided CAP can be reliably diagnosed with positional changes during routine echocardiography.